Evidence map›Paper›PMID 42707793›Full record

ReviewFrontiers in immunology2026

Targeting S100A8/A9: a molecular gateway to oral inflammation, microglial activation and neuroinflammation.

Jonaid Ahmad Malik, Tooba Qamar, Abrar H Qadri, Iqball Faheem

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jonaid Ahmad MalikDepartment of Biomedical Engineering, Indian Institute of Technology, Ropar, India.
Tooba QamarDepartment of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, Uttar Pradesh, India.
Abrar H QadriDepartment of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, TG, India.
Iqball FaheemDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

S100A8 and S100A9 are critical members of the S100 protein family with diverse immunoregulatory functions, serving as important mediators of neuroimmune communication and key links between inflammation, microglial activation, and neurodegenerative processes. S100A8 and S100A9 are abundantly expressed in neutrophils, monocytes, and other immune cells and are rapidly released during inflammatory responses. Once extracellular, S100A8/A9 interacts with cell-surface pattern-recognition receptors, including TLR4 and RAGE, triggering downstream NF-κB and MAPK signaling cascades that drive pro-inflammatory cytokine production. S100A8/A9 has also been implicated in activating the intracellular NLRP3 inflammasome sensor/scaffold, a pro-inflammatory response associated with neuroinflammation. Growing evidence indicates that dysregulated S100A8/A9 expression contributes to both central and peripheral inflammatory pathologies and is elevated across multiple disease states. This review provides a comprehensive analysis of the S100A8/A9 signaling axis, examining its structural and functional roles in regulating microglial activation and neuroimmune crosstalk. It further explores the role of S100A8/A9 signaling in the pathogenesis of diverse inflammatory and neurodegenerative disorders, highlighting the underlying molecular mechanisms. By integrating current knowledge, this review highlights the therapeutic potential of targeting the S100A8/A9 to modulate neuroinflammation and facilitate the development of more effective interventions for neurodegenerative diseases.

Indexed as

Calgranulin ACalgranulin BMicrogliaNeuroinflammatory DiseasesAnimalsHumansInflammationSignal TransductionCalgranulin ACalgranulin Bmicroglia activationneuroimmune communicationneuroinflammationNLRP3 inflammasomeprotein therapeuticsrageS100A8/A9salivary biomarkers

Identifiers

PMID42707793
PMCPMC13548118

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.